Neurosense Therapeutics is trading 12.61% lower at $3.05; no confirmed overnight company announcement directly explains the intraday drop. - Its Nasdaq appeal remains unresolved, with a November 10 hearing over the outstanding $35 million market-value listing requirement; shares continue trading while the appeal is pending. - September headline CPI was 3.7% year over year, above the 3.6% forecast, and U.S. stocks weakened amid renewed rate concerns; biotech was down 2.01%.